Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | VDR | P11473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015284 | 0.88 | FFAR1 (0.52) | MTNR1APPARGMEN1KMT2ALMNA | |
| SCHEMBL6380266 | 0.84 | PPARG (0.54) | PPARGMEN1KMT2ATP53MAPT | |
| SCHEMBL6476520 | 0.82 | PPARG (0.56) | MTNR1APPARGPPARDCNR1CNR2 | |
| SCHEMBL6477814 | 0.81 | PPARG (0.58) | MTNR1APPARGMEN1KMT2AMAPT | |
| SCHEMBL6477969 | 0.79 | MTNR1A (0.48) | MTNR1APPARGLTA4HPPARD | |
| SCHEMBL6486348 | 0.78 | MTNR1A (0.50) | MTNR1AMEN1KMT2AMAPTCNR1 | |
| SCHEMBL7824667 | 0.75 | MTNR1A (0.59) | MTNR1ACNR1CNR2 | |
| SCHEMBL6486014 | 0.75 | MTNR1A (0.47) | MTNR1AMEN1KMT2AMAPTLTA4H | |
| SCHEMBL7016025 | 0.74 | TBXAS1 (0.57) | MTNR1AMEN1KMT2ALMNATHRB | |
| SCHEMBL7016021 | 0.74 | TBXAS1 (0.57) | MTNR1AMEN1KMT2ALMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919362-B2 | Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2005-07-19 | — | — | US | disclosed |
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | CYP2F1, CYP11B2, CYP4B1 | MTNR1A 1004/4885PPARG 414/4885MEN1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.